- Report
- February 2025
- 200 Pages
Global
From €4081EUR$4,490USD£3,495GBP
- Report
- January 2025
- 135 Pages
Global
From €2726EUR$2,999USD£2,334GBP
- Clinical Trials
- December 2024
- 60 Pages
Global
From €1363EUR$1,500USD£1,167GBP
- Report
- April 2025
- 50 Pages
Global
From €2409EUR$2,650USD£2,062GBP
- Report
- April 2025
- 50 Pages
Global
From €2409EUR$2,650USD£2,062GBP
- Book
- July 2009
- 1116 Pages
Primidone is a medication used to treat certain types of seizures, including grand mal, psychomotor, and focal seizures. It is a member of the barbiturate class of drugs and is classified as an anticonvulsant. Primidone is used to reduce the frequency and severity of seizures, and is often used in combination with other anticonvulsants. It is also used to treat essential tremor, a condition characterized by involuntary shaking of the hands and arms. Primidone is available in both generic and brand-name formulations.
Primidone is a key player in the Central Nervous System Drugs market. It is used to treat a variety of neurological conditions, including epilepsy, essential tremor, and other seizure disorders. Primidone is often used in combination with other anticonvulsants, and is available in both generic and brand-name formulations.
Some companies in the Primidone market include Pfizer, GlaxoSmithKline, Novartis, Sanofi, and Mylan. Show Less Read more